Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: Two cooperative phase II studies of the AIO/ ARO/ACO

Annals of Oncology

Volumn 16, Issue 8, 2005, Pages 1326-1333

  Kollmannsberger, C ^a,b   Budach, W ^a,c   Stahl, M ^d   Schleucher, N ^e   Hehr, T ^a   Wilke, H ^d   Schleicher, J ^f   Vanhoefer, U ^e   Jehle, E C ^g   Oechsle, K ^a   Trarbach, T ^e   Boehlke, I ^a   Kanz, L ^a   Hartmann, J T ^a   Bokemeyer, C ^a,h  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d KLINIKEN ESSEN MITTE   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f KATHARINENHOSPITAL   (Germany)

^g Oberschwabenklinik ^*  (Germany)

^h UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Adjuvant chemoradiation; Feasibility; Gastric cancer; Toxicity

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 23844525579     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi252     Document Type: Article

References (29)

1. Gunderson LL. Gastric cancer-patterns of relapse after surgical resection. Semin Radiat Oncol 2002; 12: 150-161.
2. Landry J, Tepper JE, Wood WC et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990; 19: 1357-1362.
3. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: 5th edition, American Joint Committee on cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 2000; 88: 921-932.
4. Lise M, Nitti D, Marchet A et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763.
5. Coombes RC, Schein PS, Chilvers CE et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990; 8: 1362-1369.
6. Macdonald JS, Fleming TR, Peterson RF et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494.
7. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-1064.
8. Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-843.
9. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up. Lancet 1994; 343: 1309-1312.
10. Zhang ZX, Gu XZ, Yin WB et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys 1998; 42: 929-934.
11. Macdonald JS, Smalley S, Benedetti J et al. Chemoradiation after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
12. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
13. Vanhoefer U, Wagener T, Lutz M et al. Randomized phase II study of weekly 24h infusion of high dose 5-FU ± folinic acid (HDFU ± FA) vs HD-5-FU/FA/biweekly cisplatin in advanced gastric cancer. Eur J Cancer 2001; 37(S27): (Abstr 88).
14. Kollmannsberger C, Quietzsch D, Haag C et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83: 458-462.
15. Louvet C, Andre T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-4548.
16. Bouche O, Raoul JL, Bonnetain F et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328.
17. Wilke H, Korn M, Köhne C et al. Phase II results of weekly infusional high-dose FU (HD-FU) plus folinic acid (FA) and biweekly cisplatin (C) in advanced gastric cancer. Ann Oncol 1996; 7 (Suppl 5): 46.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am J Stat Assoc 1958; 53: 457-481.
19. Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol 2003; 4: 498-505.
20. Bajetta E, Buzzoni R, Mariani L et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
21. Ajani JA, Mansfield PF, Janjan N et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22: 2774-2780.
22. Honecker F, Kollmannsberger C, Quietzsch D et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 2002; 13: 497-503.
23. Chun H, Puccio C, Olson C et al. Cisplatin plus concurrent continuous infusion (CI) of 5-fluroruracil (5-FU) and paclitaxel: Active regimen for adenocarcinoma of the stomach and gastroesophageal junction (GEJ). Proc Am Soc Clin Oncol 2000; 19: Abstr 1058.
24. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295-301.
25. Kohne CH, Wils J, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21: 3721-3728.
26. Henning GT, Schild SE, Stafford SL et al. Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 589-598.
27. Leong T, Michael M, Foo K et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br J Cancer 2003; 89: 1433-1438.
28. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999; 340: 908-914.
29. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.